CRNXGBP: Crinetics Pharmaceuticals In insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
268 institutions reported holding $4.25B of Crinetics Pharmaceuticals In on Form 13F (245 the quarter before). 53 opened a new position and 31 sold out. Shares held by institutions: +1%.
| Largest holders | Shares | Value |
|---|---|---|
| FMR LLC | 15,840,219 | $592.74M |
| BlackRock, Inc. | 9,758,938 | $365.18M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 8,989,098 | $336.37M |
| WELLINGTON MANAGEMENT GROUP LLP | 7,131,084 | $266.85M |
| Driehaus Capital Management LLC | 6,463,551 | $241.87M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,832,614 | $180.84M |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,745,262 | $177.57M |
| Jupiter Topco LLC | 4,557,689 | $170.51M |
| GEODE CAPITAL MANAGEMENT, LLC | 2,727,633 | $102.09M |
| STATE STREET CORP | 2,689,350 | $100.64M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.